NEUMOLOGÍA PEDIÁTRICA

Neumol Pediatr 2020; 15 (2): 301 - 307 C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl 306 Otro desafío de la naturaleza: el nuevo coronavirus. Virología y fisiopatología del SARS-COV-2 Figura 4. Patogenia postulada de infección por SARS-COV-2. SRA: sistema renina– angiotensina. SDRA: síndrome de dificultad respiratoria aguda. (Imagen de Yuefei, Jin, modificada y adaptada). REFERENCIAS 1. LePan N. Visualizing the history of pandemics. https:// www. v i s u a l c a p i t a l i s t . c om/ h i s t o r y - o f - p a n d em i c s - deadliest/ 2. Avendaño L.F. Cap.12. Infecciones virales respiratorias. En. Avendaño LF, Ferrés M, Luchsinger V, Spencer E. Virología Clínica. Mediterráneo 2ª Ed. Santiago 2018. 3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al., Coronavirus Investigating, and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020, http://dx.doi.org/10.1056/ NEJMoa2001017. 4. Calvo C, et al. Recomendaciones sobre el manejo clínico de la infección por el «nuevo coronavirus» SARS-CoV2. Grupo de trabajo de la Asociación Espanola de Pediatría (AEP). An Pediatr (Barc). 2020. https://doi.org/10.1016/j. anpedi.2020.02.001 5. Masters PS, Perlman S. Chapter 28. Coronaviridae. En: Knipe DM, Howley PM. Fields Virology Wolster Kluwer/ Lippincott Williams & Wilkins. Philadelphia. 6th Ed. 2013 pp 825 6. Liu C, Zhou Q, Li Y et al. Research and development on therapeutic agents and Vaccines for COVID 19 and related human coronavirus diseases. ACS. https//dx.doi. org/10.1021/acscentsci.0c00272 7. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in clinical practice. International Journal of Oral Science 2020; 12:9. https:// doi.org/10.1038/s41368-020-075-9 8. Cortegiani, G. Ingoglia, M. Ippolito, et al., A systematic review on the ef cacy and safety of chloroquine for the treatment of COVID-19, Journal of Critical Care, https:// doi.org/10.1016/j.jcrc.2020.03.005 9. Li-sheng Wang, Yi-ru Wang , Da-wei Ye , Qing- quan Liu , A review of the2019 Novel Coronavirus (COVID-19) based on current evidence. International Journal of Antimicrobial Agents (2020), doi: https://doi. org/10.1016/j.ijantimicag.2020.105948. 10. Staging Proposal. Siddiqi, Hasan K. et al. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic The Journal of Heart and Lung Transplantation, Volume 0, Issue 0 11. Jin Y, Yang H , Ji W , Wu W, Chen S, Zhang W, Duan G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020 Mar 27;12(4). pii: E372. doi: 10.3390/v12040372. 12. Wan, Y, Shang, J, Graham, R, Baric, RS, and Li, F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. Journal of Virology. 2020; https://doi.org/10.1128/jvi.00127-20 13. Fu, Y., Cheng, Y. & Wu, Y. Understanding SARS-CoV-2- Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol. Sin. (2020). https:// doi.org/10.1007/s12250-020-00207-4 14. Russell, CD, Millar, JE, and Baillie, JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020; 395: 473–475https://doi.